{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"JEEFMLVJZKFOFV-FCHUYYIVSA-N","prefName":"JWH-057","symbol":"JWH-057","iupacName":"(6aR,10aR)-6,6,9-trimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene","aliases":["JWH 057","1-Deoxy-delta(8)-THC DMH","1-deoxy-Δ8-THC-DMH"],"cas":"105823-04-9","pubchemCid":"129128","chebiId":null,"smiles":"CCCCCCC(C)(C)C1=CC2=C(C=C1)[C@@H]3CC(=CC[C@H]3C(O2)(C)C)C","molecularFormula":"C25H38O","molecularWeight":354.6,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/129128"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: JWH-057 is produced by no living organism identified in the sources consulted. It belongs to chemical synthesis alone, which assembles a partially hydrogenated benzo[c]chromene nucleus and a 1′,1′-dimethylheptyl side chain on the aromatic ring.","originNote":"Synthetic molecule designed in laboratories studying cannabinoid receptors, with no established therapeutic indication. No source consulted reports it in hemp or in any other living organism. It appears in the literature around 1996, in parallel with the work of Huffman's team at Clemson University.","discovered":""},"pharmacology":{"summaryFr":"JWH-057, or 1-deoxy-Δ8-THC-DMH, is a synthetic cannabinoid designated by the JWH code, used in the work of John W. Huffman at Clemson University. It is an analogue of Δ8-THC that lacks a hydroxyl at position 1, and whose side chain at position 3 is a 1′,1′-dimethylheptyl. Huffman et al. (2010) report an affinity constant of Ki 23 ± 7 nM for CB1 and Ki 2.9 ± 1.6 nM for CB2, a selectivity of nearly ten-fold for CB2. The authors describe it as potent in vivo. No human data were found in the sources consulted, and no therapeutic indication is established. In France, it falls under a generic clause of the narcotics list.","receptorSummaryFr":"Presumed agonist of the CB1 and CB2 receptors. No measure of intrinsic efficacy was found in the sources consulted, but the molecule is described as potent in vivo (Huffman et al., 2010). Huffman et al. (2010) report an affinity constant of Ki 23 ± 7 nM for CB1 and Ki 2.9 ± 1.6 nM for CB2, a selectivity of nearly ten-fold for CB2. An earlier measurement published in 1996 by Gareau et al., listed in ChEMBL, gives 249.7 nM for CB1 and 20.8 nM for CB2 on human receptors. Both sets of measurements place the highest affinity on CB2.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":78,"reported":"Ki 23 ± 7 nM (Huffman et coll., 2010)","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":90,"reported":"Ki 2,9 ± 1,6 nM (Huffman et coll., 2010)","confidence":"medium"}],"references":[{"label":"Huffman et coll., 1-bromo-1-désoxy-Δ8-THC sélectifs du récepteur CB2 (série des 3-(1′,1′-diméthylalkyl) analogues), Bioorg Med Chem, 2010","pmid":"20943404","doi":"10.1016/j.bmc.2010.09.061","url":"https://pubmed.ncbi.nlm.nih.gov/20943404/"},{"label":"Huffman, recherche de ligands sélectifs du récepteur CB2 (revue), Current Pharmaceutical Design, 2000","pmid":"10903395","doi":"10.2174/1381612003399347","url":"https://pubmed.ncbi.nlm.nih.gov/10903395/"},{"label":"Gareau et coll., relations structure-activité des analogues du tétrahydrocannabinol sur les récepteurs cannabinoïdes humains, Bioorg Med Chem Lett, 1996","pmid":null,"doi":"10.1016/0960-894X(95)00573-C","url":"https://doi.org/10.1016/0960-894X(95)00573-C"},{"label":"ChEMBL, CHEMBL57723 (mesures de liaison CB1 et CB2 du JWH-057)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL57723/"},{"label":"PubChem, CID 129128 (JWH-057)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/129128"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, clause benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 modifiant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"OICS, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":5},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":10},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":15},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":10}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level was found in the sources consulted: control therefore falls under national legislation. The molecule is not on the INCB Green List 2026, which reproduces the 1961 and 1971 conventions.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Substance not named in the consolidated list of narcotics (updated 16 February 2026), but covered by a generic clause. It falls under the clause on derivatives of the benzo[c]chromene nucleus, figuring in annex IV of the decree of 22 February 1990 in the wording resulting from the decisions of 22 May 2024 and 3 June 2024. This clause covers any substance derived from this nucleus, unhydrogenated, partially or fully hydrogenated on the ring bearing the methyl at position 9, and substituted or not at positions 1, 2, 3, 4, 6 and 9 according to the types listed. JWH-057 meets each of these conditions: a partially hydrogenated benzo[c]chromene nucleus on this ring, a branched alkyl chain at position 3, two alkyl groups at position 6 and one alkyl group at position 9. It falls under none of the clause's exclusions (CBN, CBNA, THCV, THCA). Its production, possession, transfer and use therefore fall under the criminal narcotics regime. It therefore cannot be legally sold in France.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Huffman et coll., 1-bromo-1-désoxy-Δ8-THC sélectifs du récepteur CB2 (série des 3-(1′,1′-diméthylalkyl) analogues), Bioorg Med Chem, 2010","pmid":"20943404","doi":"10.1016/j.bmc.2010.09.061","url":"https://pubmed.ncbi.nlm.nih.gov/20943404/"},{"label":"Huffman, recherche de ligands sélectifs du récepteur CB2 (revue), Current Pharmaceutical Design, 2000","pmid":"10903395","doi":"10.2174/1381612003399347","url":"https://pubmed.ncbi.nlm.nih.gov/10903395/"},{"label":"Gareau et coll., relations structure-activité des analogues du tétrahydrocannabinol sur les récepteurs cannabinoïdes humains, Bioorg Med Chem Lett, 1996","pmid":null,"doi":"10.1016/0960-894X(95)00573-C","url":"https://doi.org/10.1016/0960-894X(95)00573-C"},{"label":"ChEMBL, CHEMBL57723 (mesures de liaison CB1 et CB2 du JWH-057)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL57723/"},{"label":"PubChem, CID 129128 (JWH-057)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/129128"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV, clause benzo[c]chromène)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"ANSM, décision du 22 mai 2024 modifiant la liste des substances classées comme stupéfiants","pmid":null,"doi":null,"url":"https://ansm.sante.fr/actualites/decision-du-22-05-2024-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants"},{"label":"OICS, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"jwh-057","url":"https://en.phytogrammes.com/wiki/jwh-057","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}